In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
GlobeNewswire
First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates
Sanofi and BioMed X Team Up to Use AI for Drug Development
Yahoo! Finance
This is the first joint research project between Sanofi and the BioMed X Institute for the co-creation of a next-generation virtual patient engine for the clinical translation of drug candidates.
Sanofi and BioMed X Team Up to Use AI for Drug Development
Corpradar
This research collaboration will address one of the most important bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. The aim is to transform the practice of medicine with the use of digital data and artificial intelligence, and thus, this project will benefit from Sanofi’s deep datasets and expertise.
Sanofi and BioMed X Partner to Predict Efficacy with Virtual Patient Populations
BioSpace
BioMed X and Sanofi have inked an R&D collaboration to use digital data and artificial intelligence to predict the efficacy of first-in-class drug candidates using virtual patient populations. As it stands, there is a 90% failure rate of new drug candidates during clinical development, an issue that this new project aims to tackle.
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
BioSpace
First joint research project between Sanofi and the BioMed X Institute for the co-creation of a next-generation virtual patient engine for clinical translation of first-in-class drug candidates.
BioMed X Inks Research Collaboration With Sanofi on Artificial Intelligence for Drug Development
Financial Content
BioMed X announced today the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg, Germany, will focus on the development of a versatile computational platform able to accurately predict the efficacy of first-in-class drug candidates in virtual patient populations.
Sanofi, BioMed X Enter into AI-Based Drug Development Collaboration
Pakistan Tech News
BioMed X, an independent research organization from Heidelberg, Germany, announced that it has signed a research collaboration with Sanofi to develop an artificial intelligence (AI) computational platform for predicting the efficacy of first-in-class drugs using a virtual patient population. The initial proof-of-concept phase of the collaboration will focus on immune-induced chronic diseases, including atopic dermatitis and inflammatory bowel disease.
BioMed X and Sanofi partner to leverage AI for drug development
Pharmaceutical Technology
BioMed X and Sanofi partner to leverage AI for drug development. Chronic immune-mediated diseases will be the focus area of the preliminary model.
Sanofi, BioMed X Enter AI-Based Drug Development Collaboration
Inside Precision Medicine
First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates
AION Labs Launches AI Startup Addressing Drug Trial Improvement
PR Newswire
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X
Pfizer, AstraZeneca, Merck KGaA-backed Israeli AI incubator launches first biopharma startup
Fierce Biotech
After Pfizer, AstraZeneca, Teva & Merck KGaA backed an Israeli startup incubator looking to use AI in drug development, they’re now celebrating the launch of their first company. AION Labs is raising the curtain on OMEC.AI, a venture tasked with employing machine learning to help predict which drug candidates will be most likely to succeed in clinical trials.
AION Labs launches AI startup to improve drug trials
Labiotech.eu
AION Labs has formed OMEC.AI, the lab’s first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the probability of success of drug candidates in clinical trials.
AION Labs Launches AI Startup Addressing Drug Trial Improvement
AITHORITY
AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced the formation of OMEC.AI, the lab’s first startup approved by the Israel Innovation Authority. The new company will develop AI-powered solutions to analyze pre-clinical data and identify gaps in efficacy and safety to improve the success probability of drug candidates.
Mobileye vets launch start-up to assess what drugs should go to trial
The Jerusalem Post
OMEC.AI, founded by Ori Shachar and Amir Harel, aims to transform the process of drug discovery and development for the betterment of human health.
AION Labs Launches AI Startup Addressing Drug Trial Improvement
Mobile Health Times
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X OMEC.AI will use advanced machine learning to improve probability of success for drug candidates in clinical trials.